Published in Aliment Pharmacol Ther on June 15, 2005
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Kyoto global consensus report on Helicobacter pylori gastritis. Gut (2015) 1.47
Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol (2010) 1.24
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol (2008) 1.04
Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol (2012) 1.03
The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol (2013) 0.98
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf (2009) 0.94
Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine. J Clin Biochem Nutr (2008) 0.93
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92
Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf (2015) 0.89
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol (2012) 0.88
Assessing the risks and benefits of treating Helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.85
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol (2006) 0.85
Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol (2014) 0.83
Helicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption. World J Gastroenterol (2011) 0.81
Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone. Therap Adv Gastroenterol (2008) 0.81
Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis (2013) 0.80
Helicobacter pylori and NSAID-induced gastric ulcer in a Japanese population. J Gastroenterol (2009) 0.79
Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol (2014) 0.79
Potential role of probiotics in the management of gastric ulcer. Exp Ther Med (2016) 0.79
Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clin Res Cardiol (2014) 0.78
Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol (2016) 0.78
Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies. Pharmaceuticals (Basel) (2010) 0.77
COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori. Clin Med Insights Gastroenterol (2013) 0.77
Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. Gut Liver (2013) 0.76
Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations. Open Access Rheumatol (2011) 0.75
Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study. Dig Dis Sci (2010) 0.75
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin. Drug Healthc Patient Saf (2010) 0.75
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. Core Evid (2007) 0.75
Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance. Gastroenterol Hepatol (N Y) (2014) 0.75
Assessment of the environmental risk factors for a gastric ulcer in northern Ghana. Pan Afr Med J (2016) 0.75
Contemporary Diagnostic Strategies for the Detection of Helicobacter pylori Infection. Gastroenterol Hepatol (N Y) (2012) 0.75
Upper Gastrointestinal Bleeding in Children: The Role of Helicobacter pylori Infection and Non-steroidal Anti-inflammatory Drug Use. West Indian Med J (2015) 0.75
Perforated peptic ulcer - an update. World J Gastrointest Surg (2017) 0.75
Is perforated marginal ulcer after the surgery of gastroduodenal ulcer associated with inadequate treatment for Helicobacter pylori eradication? Langenbecks Arch Surg (2007) 0.75
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut (2010) 2.98
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther (2010) 2.51
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther (2012) 2.25
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00
Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther (2009) 1.83
Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther (2001) 1.80
Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther (2014) 1.78
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol (2005) 1.67
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther (2011) 1.63
Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med (2002) 1.57
13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis (2000) 1.51
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther (2011) 1.50
Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Endoscopy (1995) 1.48
[Guidelines for the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding]. Gastroenterol Hepatol (2003) 1.47
Prevalence of Helicobacter pylori infection in medical professionals in Spain. Eur J Gastroenterol Hepatol (1999) 1.42
Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis (2007) 1.39
Epidemiology of inflammatory bowel disease in Spain. A systematic review. Rev Esp Enferm Dig (2001) 1.39
Commentary: comparators in H. pylori eradication--stating the ethics of statins. Aliment Pharmacol Ther (2012) 1.38
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.36
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.33
Identification of factors that influence tolerance of upper gastrointestinal endoscopy. Eur J Gastroenterol Hepatol (1999) 1.30
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther (2011) 1.22
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther (2011) 1.22
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2011) 1.21
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem (1991) 1.20
The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther (2011) 1.15
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther (2010) 1.14
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.14
Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers. Cochrane Database Syst Rev (2007) 1.14
Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother (1999) 1.11
Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther (2008) 1.09
Letter: acute severe ulcerative colitis - should all patients be treated equally? Aliment Pharmacol Ther (2014) 1.08
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther (2003) 1.08
Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic oesophagitis - still a long way to go. Aliment Pharmacol Ther (2014) 1.08
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease. Aliment Pharmacol Ther (2014) 1.08
Letter: the irony of oral iron - not an underdog for post-gastrointestinal bleeding anaemia. Aliment Pharmacol Ther (2014) 1.08
Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther (2011) 1.07
Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther (2011) 1.07
Letter: infliximab in severe ulcerative colitis - is it useful for all patients? Aliment Pharmacol Ther (2013) 1.07
Usefulness of manometry to select patients with anal fissure for controlled anal dilatation. Rev Esp Enferm Dig (2010) 1.07
Letter: mucosal healing in ulcerative colitis--higher relevance than in Crohn's disease? Aliment Pharmacol Ther (2013) 1.07
Letter: Persisting clinical symptoms in microscopic colitis in remission. Aliment Pharmacol Ther (2014) 1.07
H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev (2004) 1.07
Letter: PPI-responsive oesophageal eosinophilia--from initial scepticism to consistent prospective data. Aliment Pharmacol Ther (2014) 1.06
Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. Aliment Pharmacol Ther (2013) 1.06
Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward. Aliment Pharmacol Ther (2013) 1.06
Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Aliment Pharmacol Ther (2013) 1.06
Letter: Bismuth quadruple therapy with Pylera for H. pylori infection. Aliment Pharmacol Ther (2014) 1.05
Letter: psychological remission - a future endpoint in inflammatory bowel disease? Aliment Pharmacol Ther (2014) 1.05
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 1.05
[Sedation in digestive endoscopy. Results of a hospital survey in Catalonia (Spain)]. Gastroenterol Hepatol (2004) 1.04
Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Aliment Pharmacol Ther (2014) 1.04
Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.02
Factors predicting failure of endoscopic injection therapy in bleeding duodenal ulcer. Gastrointest Endosc (1996) 1.01
Collagenous colitis in Spain: a report of nine new cases. Rev Esp Enferm Dig (1999) 1.00
Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther (2004) 0.99
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther (2008) 0.99
Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther (2012) 0.99
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther (2013) 0.97
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther (2002) 0.96
Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings. Aliment Pharmacol Ther (2013) 0.96
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther (2000) 0.96
Nonselective cation channels as effectors of free radical-induced rat liver cell necrosis. Hepatology (2001) 0.95
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2008) 0.95
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther (2001) 0.94
[Bronchial carcinoid tumor: a retrospective analysis of 62 surgically treated cases]. Arch Bronconeumol (2004) 0.93
Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut (1996) 0.93
Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther (2004) 0.92
Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol (2012) 0.91
Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol (1997) 0.91
Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology (1994) 0.90
Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther (2011) 0.90
Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89
Angiogenesis in inflammatory bowel disease. Eur J Clin Invest (2008) 0.89
Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int Suppl (1998) 0.89
[Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review]. Rev Esp Enferm Dig (2007) 0.89
Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther (2007) 0.89
Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer (1990) 0.89
Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol (2012) 0.89
Candida albicans costochondritis in heroin addicts. Ann Thorac Surg (1986) 0.87
[Endoscopic choledochoduodenostomy in the treatment of impacted calculi in Vater's papilla]. Rev Esp Enferm Dig (1991) 0.87
Urticarial reaction to oral polyethylene glycol electrolyte lavage solution. Gastrointest Endosc (1992) 0.87